ArticleScientific reports2022
Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 63 citations in OpenAlex.
- Design and Evaluation of a Multi-Epitope Vaccine Targeting Conserved Envelope and NS5 Proteins of Usutu Virus Using Immunoinformatics.Microorganisms · 2026Article
- Designing a novel and effective multi-epitope subunit vaccine against human astrovirus using reverse vaccinology approach.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Design and in silico evaluation of an mRNA vaccine against HTLV-1 using AI-driven reverse vaccinology approaches.PloS one · 2026Article
- Vaccine Design againstFrontiers in dentistry · 2026Article
- Reverse vaccinology-based identification of immunogenic membrane proteins from zoonotic multidrug-resistant Proteus vulgaris: a one health approach to cross-species vaccine development.BMC veterinary research · 2025Article
- Alternative therapeutic approaches for combating multi-drug-resistant bacteria: Reverse vaccinology against Enterobacter cloacae.Journal, genetic engineering & biotechnology · 2025Article
- An immunoinformatics approach in designing high-coverage mRNA multi-epitope vaccine against multivariant SARS-CoV-2.Journal, genetic engineering & biotechnology · 2025Article
- Article
- Review
- Development of a novel multiepitope vaccine against Menangle virus (MenV) using in-silico approaches by targeting its transmembrane proteins.Scientific reports · 2025Article
- A new vaccination approach for Salmonellosis employing a multi-epitope vaccine based on live microbial cell factory from Lactococcus lactis.Poultry science · 2025Article
- Comprehensive Review on Viral RNA Extraction Strategies for Enhanced Molecular Diagnostics.Interdisciplinary perspectives on infectious diseases · 2025Review
- Rational design of an epitope-centric vaccine againstFrontiers in immunology · 2025Article
- Immunoinformatics Design of a Multiepitope Vaccine (MEV) TargetingPathogens (Basel, Switzerland) · 2024Article
- T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases.Vaccines · 2024Review
- Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced byPharmaceutics · 2024Article
- Article
- Immunoinformatics and Reverse Vaccinology Approach for the Identification of Potential Vaccine Candidates againstMicroorganisms · 2024Article
- Designing a conjugate vaccine targetingHeliyon · 2024Article
- Proteomics-based vaccine targets annotation and design of multi-epitope vaccine against antibiotic-resistant Streptococcus gallolyticus.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ebola virus (EBOV) is a dangerous zoonotic infectious disease. To date, more than 25 EBOV outbreaks have been documented, the majority of which have occurred in Central Africa. The rVSVG-ZEBOV-GP vaccine (ERVEBO), a live attenuated vaccine, has been approved by the US Food and Drug Administration (FDA) to combat EBOV. Because of the several drawbacks of live attenuated vaccines, multi-epitope vaccines probably appear to be safer than live attenuated vaccines. In this work, we employed immunoinformatics tools to design a multi-epitope vaccine against EBOV. We collected sequences of VP35, VP24, VP30, VP40, GP, and NP proteins from the NCBI database. T-cell and linear B-cell epitopes from target proteins were identified and tested for antigenicity, toxicity, allergenicity, and conservancy. The selected epitopes were then linked together in the vaccine's primary structure using appropriate linkers, and the 50S ribosomal L7/L12 (Locus RL7 MYCTU) sequence was added as an adjuvant to the vaccine construct's N-terminal. The physicochemical, antigenicity, and allergenicity parameters of the vaccine were all found to be satisfactory. The 3D model of the vaccine was predicted, refined, and validated. The vaccine construct had a stable and strong interaction with toll-like receptor 4 (TLR4) based on molecular docking and molecular dynamic simulation (MD) analysis. The results of codon optimization and in silico cloning revealed that the proposed vaccine was highly expressed in Escherichia coli (E. coli). The findings of this study are promising; however, experimental validations should be carried out to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.